Immune Deficiency, Cancer Predisposition & Precision Oncology

Assoc. Prof. Dr. Kaan Boztug (MD) Our group works at the interface of  inborn immune disorders and inherited predisposition to childhood tumors, aiming  to understand fundamental mechanisms of immune surveillance relevant to pediatric oncology and immunotherapy approaches. In close collaboration with several other groups at the institute and the St. Anna Children’s Hospital next door, we aim to translate the molecular understanding of childhood cancer (predisposition) to specific pathway modulations for the identification of targeted treatment approaches for pediatric cancer patients.

Development of Cellular Therapeutics

Univ.-Prof. Dr. Wolfgang Holter (MD) Our group focuses on the development of therapeutic strategies based on T cells modified with chimeric antigen receptors (CARs).

Clinical Cell Biology and FACS Core Unit

Priv.-Doz. Dr. René Geyeregger (PhD) With our engagement in flow cytometry and GMP-compliant work, we are a supportive interface between research and therapy.

Tumour Immunoediting

Dr. Eva Maria König (PhD) We study the role of NK cells in tumor immunoediting and aim to identify the molecular mechanisms of tumor immune evasion.